Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

 

By Healthcare Edge Editorial Staff

Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors.

The acquisition gives Eterna an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs), the biotech company said in a statement.

The terms of the acquisition include an upfront payment in shares of Eterna common stock, as well as milestone and other potential payments totaling up to $49 million, it said.

“With Exacis’ pipeline of engineered iPSC-derived cell therapy candidates, we believe Eterna is well-positioned to develop more effective, targeted and highly differentiated medicines to treat cancer,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna.

 

Contact:

Healthcare Edge

executives-edge.com/healthcare-edge

Editor@Executives-edge.com

Read more here: Source link